Myungmoon Pharmaceutical Rises 6.26% Amid COVID-19 (Nafamostat) Theme Uptrend

On the 14th, the COVID-19 (Nafamostat) theme rose by 5.63% compared to the previous day, showing strength, while Myungmoon Pharmaceutical, which is attracting attention as a related stock, surged by 6.26% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focused on prescription drugs.

[Graph] Major stock price changes in the COVID-19 (Nafamostat) theme

According to provisional data compiled at 10:50 AM, foreign investors are selling off a large volume of Myungmoon Pharmaceutical shares, with net foreign sales of -95,900 shares.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 5.63 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (Nafamostat). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness from a financial perspective compared to other stocks. On the other hand, Chong Kun Dang Holdings ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.